From: Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
Cause of deaths | Age group | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
20–24 | 25–29 | 30–34 | 35–39 | 40–44 | 45–49 | 50–54 | 55–59 | 60–64 | 65–69 | 70–74 | 75–79 | |
Intracranial haemorrhage | 0.2 | 0.1 | 0.4 | 0.9 | 2 | 3.5 | 5.2 | 6.7 | 8.6 | 13.6 | 21.4 | 42 |
Ischemic stroke | 0 | 0 | 0.1 | 0.1 | 0.2 | 0.6 | 0.8 | 1.5 | 3.1 | 7.4 | 16.9 | 45.4 |
Subarachnoid haemorrhage | 0.1 | 0.3 | 0.7 | 1.3 | 2.4 | 4.7 | 6.3 | 7.1 | 8.8 | 11.3 | 16.1 | 25.2 |